Cabotegravir and rilpivirine (co-packaged)

Cabotegravir and rilpivirine (co-packaged)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parth Vikram Singh, MBBS[2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Cabotegravir and rilpivirine (co-packaged) is an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non‑nucleoside reverse transcriptase inhibitor that is FDA approved for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV‑1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.. Common adverse reactions include injection site reactions, pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

• CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

Dosage and Administration Overview

• CABENUVA contains cabotegravir extended-release injectable suspension in a single-dose vial and rilpivirine extended-release injectable suspension in a single-dose vial.
• CABENUVA must be administered by a healthcare provider by gluteal intramuscular injection.
• CABENUVA may be initiated with oral cabotegravir and oral rilpivirine prior to the intramuscular injections or the patient may proceed directly to injection of CABENUVA without an oral lead-in.
• CABENUVA can be injected monthly or every 2 months.
• Healthcare providers should discuss these 2 dosing options with the patient prior to starting CABENUVA and decide which injection dosing frequency would be the most appropriate option for the patient.

• Kit of single-dose vials of 400 mg/2 mL (200 mg/mL) of cabotegravir extended-release injectable suspension and 600 mg/2 mL (300 mg/mL) of rilpivirine extended-release injectable suspension.
• Kit of single-dose vials of 600 mg/3 mL (200 mg/mL) of cabotegravir extended-release injectable suspension and 900 mg/3 mL (300 mg/mL) of rilpivirine extended-release injectable suspension.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Cabotegravir and rilpivirine (co-packaged) in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Cabotegravir and rilpivirine (co-packaged) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

The safety and effectiveness of CABENUVA have been established in adolescents aged 12 to younger than 18 years and weighing at least 35 kg.

• Kit of single-dose vials of 400 mg/2 mL (200 mg/mL) of cabotegravir extended-release injectable suspension and 600 mg/2 mL (300 mg/mL) of rilpivirine extended-release injectable suspension.
• Kit of single-dose vials of 600 mg/3 mL (200 mg/mL) of cabotegravir extended-release injectable suspension and 900 mg/3 mL (300 mg/mL) of rilpivirine extended-release injectable suspension.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Cabotegravir and rilpivirine (co-packaged) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Cabotegravir and rilpivirine (co-packaged) in pediatric patients.

Contraindications

CABENUVA is contraindicated in patients:

• with previous hypersensitivity reaction to cabotegravir or rilpivirine

• receiving the following coadministered drugs for which significant decreases in cabotegravir and/or rilpivirine plasma concentrations may occur due to uridine diphosphate glucuronosyltransferase (UGT)1A1 and/or cytochrome P450 (CYP)3A enzyme induction, which may result in loss of virologic response:
• Anticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin
• Antimycobacterials: Rifabutin, rifampin, rifapentine
• Glucocorticoid (systemic): Dexamethasone (more than a single-dose treatment)
• Herbal product: St John’s wort (Hypericum perforatum)

Warnings

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Cabotegravir and rilpivirine (co-packaged) in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Cabotegravir and rilpivirine (co-packaged) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Cabotegravir and rilpivirine (co-packaged) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Cabotegravir and rilpivirine (co-packaged) in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Cabotegravir and rilpivirine (co-packaged) in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Cabotegravir and rilpivirine (co-packaged) in geriatric settings.

Gender

There is no FDA guidance on the use of Cabotegravir and rilpivirine (co-packaged) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Cabotegravir and rilpivirine (co-packaged) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Cabotegravir and rilpivirine (co-packaged) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Cabotegravir and rilpivirine (co-packaged) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Cabotegravir and rilpivirine (co-packaged) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Cabotegravir and rilpivirine (co-packaged) in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Administration in the drug label.

Monitoring

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Cabotegravir and rilpivirine (co-packaged) and IV administrations.

Overdosage

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Mechanism of Action in the drug label.

Structure

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Structure in the drug label.

Pharmacodynamics

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Clinical Studies in the drug label.

How Supplied

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) How Supplied in the drug label.

Storage

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Cabotegravir and rilpivirine (co-packaged) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Cabotegravir and rilpivirine (co-packaged) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Cabotegravir and rilpivirine (co-packaged) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

CABENUVA

Look-Alike Drug Names

There is limited information regarding Cabotegravir and rilpivirine (co-packaged) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.